artenimol has been researched along with Non-alcoholic Fatty Liver Disease in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cai, T; Chen, Y; Cheng, Y; Du, Y; Fu, W; Huang, Z; Li, T; Shi, H; Tan, P | 1 |
| Du, G; Hu, Y; Luo, X; Peng, X; Xiong, X; Zhai, Y | 1 |
2 other study(ies) available for artenimol and Non-alcoholic Fatty Liver Disease
| Article | Year |
|---|---|
Dihydroartemisinin alleviates steatosis and inflammation in nonalcoholic steatohepatitis by decreasing endoplasmic reticulum stress and oxidative stress.
Topics: Artemisinins; Endoplasmic Reticulum Stress; Humans; Inflammation; Liver; Non-alcoholic Fatty Liver Disease; Oxidative Stress | 2022 |
Dihydroartemisinin ameliorates the liver steatosis in metabolic associated fatty liver disease mice by attenuating the inflammation and oxidative stress and promoting autophagy.
Topics: Animals; Autophagy; Diet, High-Fat; Inflammation; Lipoproteins, HDL; Liver; Mice; Non-alcoholic Fatty Liver Disease; Oxidative Stress; Triglycerides | 2023 |